Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Liabilities: 2015-2024

Historic Total Liabilities for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $319.1 million.

  • Intellia Therapeutics' Total Liabilities fell 16.08% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year decrease of 16.08%. This contributed to the annual value of $319.1 million for FY2024, which is 27.21% up from last year.
  • As of FY2024, Intellia Therapeutics' Total Liabilities stood at $319.1 million, which was up 27.21% from $250.8 million recorded in FY2023.
  • Over the past 5 years, Intellia Therapeutics' Total Liabilities peaked at $319.1 million during FY2024, and registered a low of $149.2 million during FY2020.
  • Its 3-year average for Total Liabilities is $284.8 million, with a median of $284.5 million in 2022.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 131.76% in 2020, then fell by 11.85% in 2023.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Total Liabilities stood at $149.2 million in 2020, then soared by 70.33% to $254.2 million in 2021, then rose by 11.92% to $284.5 million in 2022, then declined by 11.85% to $250.8 million in 2023, then climbed by 27.21% to $319.1 million in 2024.